Thomas Jefferson University

Andrew Himelstein

TitleVolunteer Faculty
InstitutionThomas Jefferson University
DepartmentFaculty Records
Address833 Chestnut Street
Philadelphia PA 19107
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Shapiro CL, Himelstein AL. Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer. JAMA Oncol. 2018 04 01; 4(4):585-586. PMID: 29192317.
      Citations:    
    2. Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ. Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance). J Clin Oncol. 2017 Dec 10; 35(35):3949-3955. PMID: 29023215.
      Citations:    
    3. Himelstein AL, Loprinzi CL, Shapiro CL. Zoledronic Acid Dosing Interval for Metastatic Cancer-Reply. JAMA. 2017 04 11; 317(14):1478. PMID: 28399247.
      Citations:    
    4. Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol. 2017 Feb 16. PMID: 28208174.
      Citations:    
    5. Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL. Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA. 2017 01 03; 317(1):48-58. PMID: 28030702.
      Citations:    
    6. Himelstein AL. Earlier hospice referrals help patients, families, and physicians. Del Med J. 2006 Oct; 78(10):381-2. PMID: 17076116.
      Citations:    
    7. Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE, Godwin AK, Negrini M, Croce CM. The BCSC-1 locus at chromosome 11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11517-22. PMID: 14504409.
      Citations:    
    8. Guarino MJ, Schneider CJ, Grubbs SS, Biggs DD, Himelstein AL, Hogaboom K, Tilak S. A dose-escalation study of weekly topotecan, cisplatin, and gemcitabine front-line therapy in patients with inoperable non-small cell lung cancer. Oncologist. 2002; 7(6):509-15. PMID: 12490738.
      Citations:    
    Himelstein's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (52)
    Explore
    _
    Co-Authors (2)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _